Amid criticism that the CEO was making too much money, a pharmaceutical CEO will take a pay cut.
Boston Business Journal BioFlash editor Don Seiffert joins necn to discuss his story, "Vertex cut CEO pay by 23% last year amid executive-pay overhaul."